Xbiome, a China‑based AI‑driven microbiome drug development company, announced a technology collaboration deal with Biogent...
According to the latest announcement from the Center for Drug Evaluation (CDE) of the National...
ACROBiosystems Co., Ltd. (SHE: 301080) and Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd. have entered into...
Celgenyx, Inc. announced today that CG101, its self‑developed off‑the‑shelf immune cell therapy product for the...
China’s National Medical Products Administration (NMPA) has released for public comment the “Implementation Rules for...
TJ Biopharma and Biogen Inc. (NASDAQ: BIIB) announced today that felzartamab for injection (brand name:...
IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition...
Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement...
Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on...
Shanghai Ark Biopharmaceutical Co., Ltd. announced that its independently developed first-in-class long-acting antiviral drug-Fc conjugate...
Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food...
AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its SHR-7590 injection has...
Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion...
IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC)...
Akeso Biopharma (HKG: 9926) announced that the National Medical Products Administration (NMPA) of China has...
Allist Pharmaceuticals (SHA: 688578) announced that it has signed a strategic collaboration agreement with ArriVent...
Kintor Pharmaceutical (HKG: 9939) announced that it has entered into an exclusive product distribution agreement...
CSPC Pharmaceutical Group (HKG: 1093) announced that it has received a USD 30 million upfront...
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that the New Drug Application (NDA) for...